Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus requiring treatment with at least 1500 mg but not greater than 2550 mg of a maximum tolerated dose of Metformin therapy for at least 8 weeks prior to screening.~* HbA1c \>= 7.0% and \<= 10.0 %~* Body mass index \<= 40 kg/m2~* Fasting C-peptide \>= 1 ng/dL~Exclusion Criteria:~* Symptomatic poorly controlled diabetes~* Recent cardiac or cerebrovascular event~* Serum creatinine \>= 1.5 mg/dL for males and \>= 1.4 mg/dL for females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin + Metformin (A) (Type: EXPERIMENTAL): Pioglitazone 15-45 mg (as needed for rescue)
- Saxagliptin + Metformin (B) (Type: EXPERIMENTAL): Pioglitazone 15-45 mg (as needed for rescue)
- Saxagliptin + Metformin (C) (Type: EXPERIMENTAL): Pioglitazone 15-45 mg (as needed for rescue)
- Placebo+ Metformin (D) (Type: PLACEBO_COMPARATOR): Pioglitazone 15-45 mg (as needed for rescue)

Based on this trial design, predict the completion outcome and termination type (if applicable).